The T-Cell Acute Lymphocytic Leukemia (T-Cell Acute Lymphoblastic Leukaemia) drugs in development market research report provides comprehensive information on the therapeutics under development for T-Cell Acute Lymphocytic Leukemia (T-Cell Acute Lymphoblastic Leukaemia), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for T-Cell Acute Lymphocytic Leukemia (T-Cell Acute Lymphoblastic Leukaemia). Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for T-Cell Acute Lymphocytic Leukemia (T-Cell Acute Lymphoblastic Leukaemia) and features dormant and discontinued products.
GlobalData tracks 69 drugs in development for T-Cell Acute Lymphocytic Leukemia (T-Cell Acute Lymphoblastic Leukaemia) by 57 companies/universities/institutes. The top development phase for T-Cell Acute Lymphocytic Leukemia (T-Cell Acute Lymphoblastic Leukaemia) is preclinical with 25 drugs in that stage. The T-Cell Acute Lymphocytic Leukemia (T-Cell Acute Lymphoblastic Leukaemia) pipeline has 53 drugs in development by companies and 16 by universities/ institutes. Some of the companies in the T-Cell Acute Lymphocytic Leukemia (T-Cell Acute Lymphoblastic Leukaemia) pipeline products market are: PersonGen BioTherapeutics (Suzhou), Beijing Boren Hospital and iCell Gene Therapeutics.
The key targets in the T-Cell Acute Lymphocytic Leukemia (T-Cell Acute Lymphoblastic Leukaemia) pipeline products market include Cells Expressing T Cell Antigen CD7 (GP40 or T Cell Leukemia Antigen or T Cell Surface Antigen Leu 9 or TP41 or CD7), Cells Expressing T Cell Surface Glycoprotein CD5 (Lymphocyte Antigen T1/Leu 1 or CD5), and Cells Expressing ADP Ribosyl Cyclase/Cyclic ADP Ribose Hydrolase 1 (Cyclic ADP Ribose Hydrolase 1 or T10 or 2′ Phospho ADP Ribosyl Cyclase/2′ Phospho Cyclic ADP Ribose Transferase or ADP Ribosyl Cyclase 1 or CD38 or EC 3.2.2.6 or EC 2.4.99.20).
The key mechanisms of action in the T-Cell Acute Lymphocytic Leukemia (T-Cell Acute Lymphoblastic Leukaemia) pipeline product include Cytotoxic To Cells Expressing T Cell Antigen CD7 (GP40 or T Cell Leukemia Antigen or T Cell Surface Antigen Leu 9 or TP41 or CD7) with 19 drugs in Phase II. The T-Cell Acute Lymphocytic Leukemia (T-Cell Acute Lymphoblastic Leukaemia) pipeline products include six routes of administration with the top ROA being Intravenous and six key molecule types in the T-Cell Acute Lymphocytic Leukemia (T-Cell Acute Lymphoblastic Leukaemia) pipeline products market including Gene-Modified Cell Therapy, and Small Molecule.
T-Cell Acute Lymphocytic Leukemia (T-Cell Acute Lymphoblastic Leukaemia) overview
T-cell acute lymphoblastic leukemia (T-ALL) is a type of blood cancer that affects T-cell lymphocytes, a type of white blood cell involved in the immune system’s function. T-ALL originates from immature T-cells in the bone marrow that fail to mature into normal functioning T-cells. These abnormal cells grow rapidly, crowding out normal blood cells (red blood cells, white blood cells, and platelets) in the bone marrow. T-ALL is more prevalent in children and adolescents than in adults. It accounts for approximately 15% of pediatric acute lymphoblastic leukemia (ALL) cases. The exact cause of T-ALL is not fully understood. However, certain risk factors have been identified, including genetic factors, exposure to high levels of radiation or certain chemicals, and certain genetic disorders or inherited syndromes.
For a complete picture of T-Cell Acute Lymphocytic Leukemia (T-Cell Acute Lymphoblastic Leukaemia)’s pipeline drug market, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
